Skip to main content
SpringerLink
Log in
Book cover

Breast Disease pp 131–143Cite as

Ductal Carcinoma In Situ

  • Chapter

  • 2085 Accesses

Abstract

Ductal carcinoma in situ (DCIS) is defined as abnormally proliferating malignant cells confined to the breast milk ducts by the basement membrane. The prognosis of DCIS with microinvasion (DCISM) is intermediate between those of DCIS and invasive ductal cancer. DCIS is diagnosed most commonly as a mammographic abnormality but can occasionally present as a palpable breast mass. Therapy for DCIS is personalized for each patient based on tumor-to-breast size ratio, mammographic appearance, margin width, and patient preference. The benefits and risks of breast-conserving surgery versus mastectomy should be discussed in detail. Overall survival after breast-conserving therapy is equivalent to mastectomy. Re-excision is recommended for positive margins and, although debated, pathologic margins less than 2 mm. For breast conservation therapy, radiation therapy is recommended to reduce the risk of local recurrence. Mastectomy is indicated in patients with persistently positive margins after attempts at breast conservation, a contraindication to radiation therapy, or diffuse, malignant-appearing calcifications or whose anxiety about local recurrence outweighs the impact of mastectomy on quality of life. Patients undergoing mastectomy for DCIS should have sentinel lymph node biopsy. Immediate breast reconstruction should be considered for patients undergoing mastectomy. Endocrine therapy such as tamoxifen is offered for 5 years to women with estrogen receptor-positive DCIS. Patients with DCIS should have annual clinical breast exams and annual mammographic imaging of all remaining breast tissue.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Desantis C, DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.

    Article  PubMed  Google Scholar 

  2. Zujewski JA, Harlan LC, Morrell DM, Stevens JL. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat. 2011;127(1):251–7.

    Article  PubMed  Google Scholar 

  3. Lynge E, Ponti A, James T, Májek O, von Euler-Chelpin M, Anttila A, et al. Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network. Eur J Cancer. 2014;50(1):185–92.

    Article  PubMed  Google Scholar 

  4. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–8.

    Article  PubMed  Google Scholar 

  5. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27(2):279–88.

    Article  PubMed  Google Scholar 

  6. Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44.

    Article  PubMed  Google Scholar 

  7. Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol. 2013;14(9):e348–57.

    Article  PubMed  Google Scholar 

  8. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013;173(19):1830–1.

    Article  PubMed  Google Scholar 

  10. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223(2):307–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14(2):370–8.

    Article  CAS  PubMed  Google Scholar 

  12. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012;72(17):4574–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–41.

    Article  CAS  PubMed  Google Scholar 

  14. Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res. 2003;23(3A):2043–51.

    CAS  PubMed  Google Scholar 

  15. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63(4):618–24.

    Article  CAS  PubMed  Google Scholar 

  17. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345(8958):1154–7.

    Article  CAS  PubMed  Google Scholar 

  18. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990;335(8688):519–22.

    Article  CAS  PubMed  Google Scholar 

  19. Kurtz JM, Amalric R, Brandone H, Ayme Y, Jacquemier J, Pietra JC, et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer. 1989;63(10):1912–7.

    Article  CAS  PubMed  Google Scholar 

  20. Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186(2):112–6.

    Article  PubMed  Google Scholar 

  21. Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF. Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature. Breast J. 2008;14(4):335–9.

    Article  PubMed  Google Scholar 

  22. de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer. 2002;94(8):2134–42.

    Article  PubMed  Google Scholar 

  23. Mirza NQ, Vlastos G, Meric F, Sahin AA, Singletary SE, Newman LA, et al. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000;7(9):656–64.

    Article  CAS  PubMed  Google Scholar 

  24. Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007;370(9586):485–92.

    Article  PubMed  Google Scholar 

  25. Menell JH, Morris EA, Dershaw DD, Abramson AF, Brogi E, Liberman L. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J. 2005;11(6):382–90.

    Article  PubMed  Google Scholar 

  26. Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830–49.

    Article  PubMed  Google Scholar 

  27. Rosen EL, Smith-Foley SA, DeMartini WB, Eby PR, Peacock S, Lehman CD. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J. 2007;13(6):545–50.

    Article  PubMed  Google Scholar 

  28. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356(13):1295–303.

    Article  CAS  PubMed  Google Scholar 

  29. Hollingsworth AB, Stough RG, O’Dell CA, Brekke CE. Breast magnetic resonance imaging for preoperative locoregional staging. Am J Surg. 2008;196(3):389–97.

    Article  PubMed  Google Scholar 

  30. Morrow M. Magnetic resonance imaging in the breast cancer patient: curb your enthusiasm. J Clin Oncol. 2008;26(3):352–3.

    Article  PubMed  Google Scholar 

  31. Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol. 2008;26(3):386–91.

    Article  PubMed  Google Scholar 

  32. Bedrosian I, Mick R, Orel SG, Schnall M, Reynolds C, Spitz FR, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003;98(3):468–73.

    Article  PubMed  Google Scholar 

  33. Darling ML, Smith DN, Lester SC, Kaelin C, Selland DL, Denison CM, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol. 2000;175(5):1341–6.

    Article  CAS  PubMed  Google Scholar 

  34. Dillon MF, McDermott EW, Quinn CM, O’Doherty A, O’Higgins N, Hill AD. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J Surg Oncol. 2006;93(7):559–63.

    Article  PubMed  Google Scholar 

  35. Rutstein LA, Johnson RR, Poller WR, Dabbs D, Groblewski J, Rakitt T. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ. Breast J. 2007;13(3):251–7.

    Article  PubMed  Google Scholar 

  36. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg. 1993;217(3):207–25.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Fowble B. Conservative surgery and radiation in the treatment of early (stages I and II) breast cancer. Long-term results. Helv Chir Acta. 1989;55(6):831–6.

    CAS  PubMed  Google Scholar 

  38. Vezeridis MP, Bland KI. Management of ductal carcinoma in situ. Surg Oncol. 1994;3(6):309–25.

    Article  CAS  PubMed  Google Scholar 

  39. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85(3):616–28.

    Article  CAS  PubMed  Google Scholar 

  40. Silverstein MJ, Cohlan BF, Gierson ED, Furmanski M, Gamagami P, Colburn WJ, et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer. 1992;28(2–3):630–4.

    Article  CAS  PubMed  Google Scholar 

  41. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, et al. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012;19(4):1137–44.

    Article  PubMed  Google Scholar 

  42. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013;20(13):4103–12.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Neuschatz AC, DiPetrillo T, Steinhoff M, Safaii H, Yunes M, Landa M, et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer. 2002;94(7):1917–24.

    Article  PubMed  Google Scholar 

  44. Hadzikadic Gusic L, McGuire KP, Ozmen T, Soran A, Thomas CR, McAuliffe PF, et al. Margin width is not predictive of residual disease on re-excision in breast conserving therapy. J Surg Oncol. 2014;109(5):426–30.

    Article  CAS  PubMed  Google Scholar 

  45. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32(14):1507–15.

    Article  PubMed  Google Scholar 

  46. Julian TB, Land SR, Fourchotte V, Haile SR, Fisher ER, Mamounas EP, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;14(8):2202–8.

    Article  PubMed  Google Scholar 

  47. Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol. 2000;7(9):636–42.

    Article  CAS  PubMed  Google Scholar 

  48. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83.

    Article  PubMed  Google Scholar 

  49. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.

    Article  PubMed  Google Scholar 

  50. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–9.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.

    Article  PubMed  Google Scholar 

  52. Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245(3):452–61.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995;75(6):1310–9.

    Article  CAS  PubMed  Google Scholar 

  54. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400–18.

    Article  CAS  PubMed  Google Scholar 

  55. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355(9203):528–33.

    Article  CAS  PubMed  Google Scholar 

  56. Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054–9.

    Article  PubMed  Google Scholar 

  57. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.

    Article  PubMed  Google Scholar 

  58. Jeruss JS, Kuerer HM, Beitsch PD, Vicini FA, Keisch M. Update on DCIS outcomes from the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. Ann Surg Oncol. 2011;18(1):65–71.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008;109(3):545–57.

    Article  PubMed  Google Scholar 

  60. Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y, et al. Characteristics associated with differences in survival among black and white women with breast cancer. JAMA. 2013;310(4):389–97.

    Article  CAS  PubMed  Google Scholar 

  61. Yao N, Matthews SA, Hillemeier MM, Anderson RT. Radiation therapy resources and guideline-concordant radiotherapy for early-stage breast cancer patients in an underserved region. Health Serv Res. 2013;48(4):1433–49.

    Article  PubMed Central  PubMed  Google Scholar 

  62. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24(9):1357–62.

    Article  PubMed  Google Scholar 

  63. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340(19):1455–61.

    Article  CAS  PubMed  Google Scholar 

  64. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Wong JS, Chen YH, Gadd MA, Gelman R, Lester SC, Schnitt SJ, et al. Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat. 2014;143(2):343–50.

    Article  PubMed  Google Scholar 

  66. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9.

    Article  PubMed  Google Scholar 

  67. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319–24.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res. 2003;9(1 Pt 2):495S–501.

    CAS  PubMed  Google Scholar 

  70. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.

    Article  CAS  PubMed  Google Scholar 

  71. Kong I, Narod SA, Taylor C, Paszat L, Saskin R, Nofech-Moses S, et al. Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol. 2014;21(1):e96–104.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol. 1998;16(4):1367–73.

    CAS  PubMed  Google Scholar 

  73. Romero L, Klein L, Ye W, Holmes D, Soni R, Silberman H, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2004;188(4):371–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, Magee-Womens Hospital, University of Pittsburgh Medical Center, 300 Halket Street, Suite 2601, Pittsburgh, PA, 15213, USA

    Priscilla McAuliffe MD, PhD, FACS

Authors
  1. Priscilla McAuliffe MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Priscilla McAuliffe MD, PhD, FACS .

Editor information

Editors and Affiliations

  1. Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. Institute of Oncology, Istanbul University, Istanbul, Turkey

    Abdullah İğci

  3. Magee-Womens Hospital of UPMC, Pittsburg, California, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

McAuliffe, P. (2016). Ductal Carcinoma In Situ. In: Aydiner, A., İğci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-22843-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22843-3_7

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22842-6

  • Online ISBN: 978-3-319-22843-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation